Adina-Gabriela Puiu, PhD Student

Adina-Gabriela Puiu
Group: Enzymology
Department: Enzymology

Research Assistant

Research interests: She is interested in understanding the implications of certain proteins in development, breast cancer and leukemia.

Currently working on

Adina is a PhD student and a Research Assistant, with experience in cell cultures, quantification of protein expression levels through Western Blotting and Immunoprecipitation, prokaryotic and eukaryotic protein expression and purification, studies on
protein structures and also mass spectrometric analysis of protein samples.

Biography

Adina has a Bachelor's degree in Biology and a Master's degree in Applied Genetics and Biotechnology from the Faculty of Biology, University of Bucharest. She is a PhD student and Research Assistant at the Institute of Biochemistry of the Romanian Academy, Department of Enzymology.

Papers

Year
  • Adina-Gabriela Vasilescu, Andrei-Mihai Vasilescu, Livia Elena Sima, Natalia Baran, Ștefan-Eugen SzedlacsekAdina-Gabriela Vasilescu et al . ""Breaking the cancer code: a novel DNA minicircle to disable STAT3 in ovarian cancer cells SKOV3"", Frontiers in Pharmacology 16(Article number: 1673427): 1 - 15, (2025)
    doi: 10.3389/fphar.2025.1673427
    IF: 4.80AI: 1.02
  • Andrei-Mihai Vasilescu, Adina-Gabriela Vasilescu, Livia Elena Sima, Cristian V.A. Munteanu, Natalia Baran, Stefan-Eugen SzedlacsekAndrei-Mihai Vasilescu et al . ""A novel cytotoxic anti-B7-H3 affibody with therapeutic potential in acute myeloid leukemia"", Frontiers in Pharmacology 16(Article number 1684226): 1 - 13, (2025)
    doi: 10.3389/fphar.2025.1684226
    IF: 4.80AI: 1.02
  • Balázs Váradi, Károly Brezovcsik, Zoltán Garda, Eniko Madarasi, Horea Szedlacsek, Rodica-Aura Badea, Andrei-Mihai Vasilescu, Adina-Gabriela Puiu, Aura Ionescu, Livia-Elena Sima, Cristian V.A. Munteanu, Simona Călăraș, Adrienn Vagner, Dezső Szikra, Ngô Minh Toàn, Tibor Nagy, Zoltán Szűcs, Stefan Eugen Szedlacsek, Gabor Nagy and Gyula Tircsó.Balázs Váradi et al . "Synthesis and characterization of a novel [52Mn]Mn-labelled affibody based radiotracer for HER2+ targeting", Inorganic Chemistry Frontiers, (2023)
    doi: 10.1039/D3QI00356F
    IF: 7.78AI: 1.01
  • Puiu, AG; Grigoras, O; Preda, MI; Constantin, M; Vasilescu, AM.Puiu et al . "Review: Comparative Analysis Between Cellular Oncogenes and Viral Oncogenes", BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY 11(3): 9939-9951, (2021)
    doi: 10.33263/BRIAC113.99399951
    IF: 0.25

Grants

Novel radiolabeled affibodies for targeted imaging and therapy 2019-2022
Acronym: Bilateral agreement no.3698/13.09.2018 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a bilateral collaboration between IBAR and ATOMKI, and the University of Debrecen and IFIN-HH participate in this project voluntarily.

Radiolabelling of affibody for tumor diagnostic and theranostic application in the nuclear medicine 2022-2024
Acronym: Bilateral agreement no.2886/15.09.2021 Romanian Academy- Hungarian Academy of Sciences
Project director: Stefan Szedlacsek

The project is agreed as a joint collaboration among IBAR, ATOMKI and UD, the latter being a cost free participant. There are two main directions envisaged by the proposed project: - receptors mapping and therapy, using an affibody against HER2 receptors, combined with an adequate radioisotope. In this respect, the specific objectives are: a) expression and purification of affibodies; b) establishing labelling procedures; c) ex vivo and/or in vivo testing of optimal compounds.

Biochemical and cellular investigations on the potential use of affibodies in leukemia therapy 2022 - 2023
Acronym: LEUKEMIA. Grant no.779/14.06.2022
Project director: Stefan Szedlacsek

Affibody molecules are highly promising therapeutic candidates due to their advantageous features like: small size, efficient delivery, straightforward engineering towards improved formats, site-directed conjugation of payloads, possibility of GMP production by chemical synthesis or inexpensive bacterial production leading to low product costs.